|
|
||||||||||
|
J Am Coll Cardiol, 2008; 51:37-45, doi:10.1016/j.jacc.2007.06.063 © 2008 by the American College of Cardiology Foundation |



* Department of Medicine, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada
Division of Geriatrics and Bloomfield Center for Aging Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada
Department of Mathematics and Statistics, McGill University, Montreal, Canada
Division of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
|| Division of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands
¶ Divisions of Cardiology and Clinical Epidemiology, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada.
Manuscript received April 9, 2007; revised manuscript received May 31, 2007, accepted June 25, 2007.
* Reprint requests and correspondence: Dr. Mark J. Eisenberg, 3755 Cote Ste Catherine, Suite A-118, Montreal, Quebec H3T 1E2, Canada. (Email: mark.eisenberg{at}mcgill.ca).
Objectives: This study was designed to determine whether statins reduce all-cause mortality in elderly patients with coronary heart disease.
Background: Statins continue to be underutilized in elderly patients because evidence has not consistently shown that they reduce mortality.
Methods: We searched 5 electronic databases, the Internet, and conference proceedings to identify relevant trials. In addition, we obtained unpublished data for the elderly patient subgroups from 4 trials and for the secondary prevention subgroup from the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) trial. Inclusion criteria were randomized allocation to statin or placebo, documented coronary heart disease,
50 elderly patients (defined as age
65 years), and
6 months of follow-up. Data were analyzed with hierarchical Bayesian modeling.
Results: We included 9 trials encompassing 19,569 patients with an age range of 65 to 82 years. Pooled rates of all-cause mortality were 15.6% with statins and 18.7% with placebo. We estimated a relative risk reduction of 22% over 5 years (relative risk [RR] 0.78; 95% credible interval [CI] 0.65 to 0.89). Furthermore, statins reduced coronary heart disease mortality by 30% (RR 0.70; 95% CI 0.53 to 0.83), nonfatal myocardial infarction by 26% (RR 0.74; 95% CI 0.60 to 0.89), need for revascularization by 30% (RR 0.70; 95% CI 0.53 to 0.83), and stroke by 25% (RR 0.75; 95% CI 0.56 to 0.94). The posterior median estimate of the number needed to treat to save 1 life was 28 (95% CI 15 to 56).
Conclusions: Statins reduce all-cause mortality in elderly patients and the magnitude of this effect is substantially larger than had been previously estimated.
| ||||||||
Related Articles
J. Am. Coll. Cardiol. 2008 51: 46-48.
J. Am. Coll. Cardiol. 2008 51: A33-A34.
This article has been cited by other articles:
![]() |
V. Bittner, D. Herrington, and N. Wenger Analyzing the Results of the Treating to New Targets Study Ann Intern Med, February 19, 2008; 148(4): 322 - 323. [Full Text] [PDF] |
||||
![]() |
G. A. Diamond and S. Kaul Prevention and treatment: a tale of two strategies. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 46 - 48. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |